Search

Your search keyword '"Voillat, Laurent"' showing total 309 results
Start Over Author "Voillat, Laurent"
309 results on '"Voillat, Laurent"'

1. Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study

Author

Dartigeas, Caroline, Quinquenel, Anne, Ysebaert, Loïc, Dilhuydy, Marie-Sarah, Anglaret, Bruno, Slama, Borhane, Le Du, Katell, Tardy, Stéphanie, Tchernonog, Emmanuelle, Orfeuvre, Hubert, Voillat, Laurent, Guidez, Stéphanie, Malfuson, Jean-Valère, Dupuis, Sandrine, Deslandes, Marine, Feugier, Pierre, and Leblond, Véronique

Published
2024
Full Text
View/download PDF

2. Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases

Author

Jachiet, Vincent, Ricard, Laure, Hirsch, Pierre, Malard, Florent, Pascal, Laurent, Beyne-Rauzy, Odile, Peterlin, Pierre, Maria, Alexandre Thibault Jacques, Vey, Norbert, D’Aveni, Maud, Gourin, Marie-Pierre, Dimicoli-Salazar, Sophie, Banos, Anne, Wickenhauser, Stefan, Terriou, Louis, De Renzis, Benoit, Durot, Eric, Natarajan-Ame, Shanti, Vekhoff, Anne, Voillat, Laurent, Park, Sophie, Vinit, Julien, Dieval, Céline, Dellal, Azeddine, Grobost, Vincent, Willems, Lise, Rossignol, Julien, Solary, Eric, Kosmider, Olivier, Dulphy, Nicolas, Zhao, Lin Pierre, Adès, Lionel, Fenaux, Pierre, Fain, Olivier, Mohty, Mohamad, Gaugler, Béatrice, and Mekinian, Arsène

Published
2023
Full Text
View/download PDF

3. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML

Author

Mekinian, Arsene, Zhao, Lin Pierre, Chevret, Sylvie, Desseaux, Kristell, Pascal, Laurent, Comont, Thibaut, Maria, Alexandre, Peterlin, Pierre, Terriou, Louis, D’Aveni Piney, Maud, Gourin, Marie-Pierre, Vey, Norbert, Rauzy, Odile Beyne, Grobost, Vincent, Bezanahary, Holy, Dimicoli-Salazar, Sophie, Banos, Anne, Wickenhauser, Stefan, De Renzis, Benoit, Durot, Eric, Natarajan-Amé, Shanti, Voillat, Laurent, Chermat, Fatiha, Lemaire, Karine, Jachiet, Vincent, Himberlin, Chantal, Thépot, Sylvain, Diaz, Jose Miguel Torregrosa, Frenzel, Laurent, Gyan, Emmanuel, Denis, Guillaume, Hirsch, Pierre, Kosmider, Olivier, Ades, Lionel, Fain, Olivier, and Fenaux, Pierre

Published
2022
Full Text
View/download PDF

4. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

Author

Schavgoulidze, Anaïs, Talbot, Alexis, Perrot, Aurore, Cazaubiel, Titouan, Leleu, Xavier, Manier, Salomon, Buisson, Laure, Mahéo, Sabrina, Do Souto Ferreira, Laura, Pavageau, Luka, Hulin, Cyrille, Marolleau, Jean-Pierre, Voillat, Laurent, Belhadj, Karim, Divoux, Marion, Slama, Borhane, Brechignac, Sabine, Macro, Margaret, Stoppa, Anne-Marie, Sanhes, Laurence, Orsini-Piocelle, Frédérique, Fontan, Jean, Chretien, Marie-Lorraine, Demarquette, Hélène, Mohty, Mohamad, Avet-Loiseau, Hervé, and Corre, Jill

Published
2023
Full Text
View/download PDF

5. Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

Author

Bobin, Arthur, Kyheng, Maéva, Guidez, Stéphanie, Gruchet-Merouze, Cécile, Richez, Valentine, Duhamel, Alain, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, Malfuson, Jean-Valère, Bourquard, Pascal, Lenain, Pascal, Perrot, Aurore, Roussel, Murielle, Jaccard, Arnaud, Petillon, Marie-Odile, Belhadj-Merzoug, Karim, Chretien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Roos-Weil, Damien, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G., Moreau, Philippe, Avet-Loiseau, Hervé, Hulin, Cyrille, Facon, Thierry, and Leleu, Xavier

Published
2022
Full Text
View/download PDF

6. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features

Author

Cazaubiel, Titouan, Leleu, Xavier, Perrot, Aurore, Manier, Salomon, Buisson, Laure, Maheo, Sabrina, Do Souto Ferreira, Laura, Lannes, Romain, Pavageau, Luka, Hulin, Cyrille, Marolleau, Jean-Pierre, Voillat, Laurent, Belhadj, Karim, Divoux, Marion, Slama, Borhane, Brechignac, Sabine, Macro, Margaret, Stoppa, Anne-Marie, Sanhes, Laurence, Orsini-Piocelle, Frédérique, Fontan, Jean, Chretien, Marie-Lorraine, Demarquette, Hélène, Mohty, Mohamad, Schavgoulidze, Anais, Avet-Loiseau, Herve, and Corre, Jill

Published
2022
Full Text
View/download PDF

7. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma

Author

Lemonnier, François, Safar, Violaine, Beldi-Ferchiou, Asma, Cottereau, Anne-Ségolène, Bachy, Emmanuel, Cartron, Guillaume, Fataccioli, Virginie, Pelletier, Laura, Robe, Cyrielle, Letourneau, Audrey, Missiaglia, Edoardo, Fourati, Slim, Moles-Moreau, Marie-Pierre, Delmer, Alain, Bouabdallah, Reda, Voillat, Laurent, Becker, Stéphanie, Bossard, Céline, Parrens, Marie, Casasnovas, Olivier, Cacheux, Victoria, Régny, Caroline, Camus, Vincent, Delfau-Larue, Marie-Hélène, Meignan, Michel, de Leval, Laurence, Gaulard, Philippe, and Haioun, Corinne

Published
2021
Full Text
View/download PDF

8. Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study

Author

Tondeur, Sylvie, Paul, Franciane, Riou, Jérémie, Mansier, Olivier, Ranta, Dana, Le Clech, Lenaïg, Lippert, Eric, Tavitian, Suzanne, Chaoui, Driss, Mercier, Mélanie, De Renzis, Benoit, Cottin, Laurane, Cassinat, Bruno, Chrétien, Jean-Marie, Ianotto, Jean-Christophe, Allangba, Olivier, Marzac, Christophe, Voillat, Laurent, Boyer, Françoise, Orvain, Corentin, Hunault-Berger, Mathilde, Girodon, François, Kiladjian, Jean-Jacques, Ugo, Valérie, and Luque Paz, Damien

Published
2021
Full Text
View/download PDF

9. Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study

Author

DARTIGEAS, Caroline, primary, QUINQUENEL, Anne, additional, YSEBAERT, Loïc, additional, DILHUYDY, Marie-Sarah, additional, ANGLARET, Bruno, additional, SLAMA, Borhane, additional, DU, Katell LE, additional, TARDY, Stéphanie, additional, TCHERNONOG, Emmanuelle, additional, ORFEUVRE, Hubert, additional, VOILLAT, Laurent, additional, GUIDEZ, Stéphanie, additional, MALFUSON, Jean-Valère, additional, DUPUIS, Sandrine, additional, DESLANDES, Marine, additional, FEUGIER, Pierre, additional, and LEBLOND, Véronique, additional

Published
2024
Full Text
View/download PDF

10. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma

Author

Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V., Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M., Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves–Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J., Lipkin, Steven M., McKay, James D., and Dumontet, Charles

Published
2019
Full Text
View/download PDF

11. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

Author

Dejoie, Thomas, Corre, Jill, Caillon, Helene, Hulin, Cyrille, Perrot, Aurore, Caillot, Denis, Boyle, Eileen, Chretien, Marie-Lorraine, Fontan, Jean, Belhadj, Karim, Brechignac, Sabine, Decaux, Olivier, Voillat, Laurent, Rodon, Philippe, Fitoussi, Olivier, Araujo, Carla, Benboubker, Lotfi, Fontan, Charlotte, Tiab, Mourad, Godmer, Pascal, Luycx, Odile, Allangba, Olivier, Pignon, Jean-Michel, Fuzibet, Jean-Gabriel, Legros, Laurence, Stoppa, Anne Marie, Dib, Mamoun, Pegourie, Brigitte, Orsini-Piocelle, Frederique, Karlin, Lionel, Arnulf, Bertrand, Roussel, Murielle, Garderet, Laurent, Mohty, Mohamad, Meuleman, Nathalie, Doyen, Chantal, Lenain, Pascal, Macro, Margaret, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, and Avet-Loiseau, Herve

Published
2016
Full Text
View/download PDF

12. What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort

Author

Perrot, Aurore, Decaux, Olivier, Royer, Bruno, Caillot, Denis, Belhadj Merzoug, Karim, Farge, Agathe, Frenzel, Laurent, Sonntag, Cécile, Slama, Bohrane, Bourgeois-Petit, Emmanuelle, Moreau, Philippe, Voillat, Laurent, Luycx, Odile, Benboubker, Lotfi, Pica, Gian-Matteo, Maloisel, Frederic, Eveillard, Jean-Richard, Algrin, Caroline, Schmitt, Anna, Garlantézec, Ronan, Texier, Nathalie, Germain, Raphael, Willaime, Marion, Hulin, Cyrille, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC), Université de Rennes (UR)-Etablissement français du sang [Rennes] (EFS Bretagne)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Necker - Enfants Malades [AP-HP], Centre Hospitalier Chalon-sur-Saône William Morey, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Institut Bergonié [Bordeaux], UNICANCER, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and CHU Pessac

Subjects
Immunology, [SDV.CAN]Life Sciences [q-bio]/Cancer, Cell Biology, Hematology, Biochemistry
Abstract

International audience; Voir également : Choix du réseau wifi à l'université de Rennes 1 Première connexion Repérer le réseau eduroam, puis s'y connecter : Le réseau eduroam est basé sur une authentification 802.1x, au niveau réseau : l'authentification de l'utilisateur est demandé dès la connexion au réseau sans-fil.

Published
2022

13. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

Author

Chretien, Marie-Lorraine, Corre, Jill, Lauwers-Cances, Valerie, Magrangeas, Florence, Cleynen, Alice, Yon, Edwige, Hulin, Cyrille, Leleu, Xavier, Orsini-Piocelle, Frederique, Blade, Jean-Sebastien, Sohn, Claudine, Karlin, Lionel, Delbrel, Xavier, Hebraud, Benjamin, Roussel, Murielle, Marit, Gerald, Garderet, Laurent, Mohty, Mohamad, Rodon, Philippe, Voillat, Laurent, Royer, Bruno, Jaccard, Arnaud, Belhadj, Karim, Fontan, Jean, Caillot, Denis, Stoppa, Anne-Marie, Attal, Michel, Facon, Thierry, Moreau, Philippe, Minvielle, Stephane, and Avet-Loiseau, Hervé

Published
2015
Full Text
View/download PDF

14. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience

Author

Hebraud, Benjamin, Magrangeas, Florence, Cleynen, Alice, Lauwers-Cances, Valerie, Chretien, Marie-Lorraine, Hulin, Cyrille, Leleu, Xavier, Yon, Edwige, Marit, Gerald, Karlin, Lionel, Roussel, Murielle, Stoppa, Anne-Marie, Belhadj, Karim, Voillat, Laurent, Garderet, Laurent, Macro, Margaret, Caillot, Denis, Mohty, Mohamad, Facon, Thierry, Moreau, Philippe, Attal, Michel, Munshi, Nikhil, Corre, Jill, Minvielle, Stephane, and Avet-Loiseau, Herve

Published
2015
Full Text
View/download PDF

16. A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

Author

Mékinian, Arsène, primary, Zhao, Lin-Pierre, additional, Desseaux, Kristell, additional, Rose, Rose, additional, Pascal, Laurent, additional, Peterlin, Pierre, additional, Comont, Thibault, additional, Maria, Alexandre, additional, Terriou, Louis, additional, d'Aveni, Maud, additional, Gourin, Marie-Pierre, additional, Vey, Norbert, additional, bayne Rouzy, Odile, additional, Dimicoli Salazar, Sophie, additional, Banos, Anne, additional, Wickenhauser, Stefan, additional, De Renzis, Benoit, additional, Durot, Eric, additional, Ame, Shanti, additional, Voillat, Laurent, additional, Chermat, Fatiha, additional, Vekhoff, Anne, additional, Lemaire, Karine, additional, Jachiet, Vincent, additional, Chevret, Sylvie, additional, Ades, Lionel, additional, Fain, Olivier, additional, and Fenaux, Pierre, additional

Published
2021
Full Text
View/download PDF

17. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Author

Corre, Jill, Perrot, Aurore, Caillot, Denis, Belhadj, Karim, Hulin, Cyrille, Leleu, Xavier, Mohty, Mohamad, Facon, Thierry, Buisson, Laure, Do Souto, Laura, Lannes, Romain, Dufrechou, Stephanie, Prade, Naïs, Orsini-Piocelle, Frederique, Voillat, Laurent, Jaccard, Arnaud, Karlin, Lionel, Macro, Margaret, Brechignac, Sabine, Dib, Mamoun, Sanhes, Laurence, Fontan, Jean, Clement-Filliatre, Lauriane, Marolleau, Jean-Pierre, Minvielle, Stephane, Moreau, Philippe, and Avet-Loiseau, Hervé

Published
2021
Full Text
View/download PDF

18. Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study

Author

Péan de Ponfilly-Sotier, Marie, primary, Jachiet, Vincent, additional, Benhamou, Ygal, additional, Lahuna, Constance, additional, De Renzis, Benoit, additional, Kottler, Diane, additional, Voillat, Laurent, additional, Dimicoli-Salazar, Sophie, additional, Banos, Anne, additional, Chauveheid, Marie-Paule, additional, Alexandra, Jean-François, additional, Grignano, Eric, additional, Liferman, François, additional, Laborde, Mathilde, additional, Broner, Jonathan, additional, Michel, Marc, additional, Lambotte, Olivier, additional, Laribi, Kamel, additional, Venon, Marie-Dominique, additional, Dussol, Bertrand, additional, Martis, Nihal, additional, Thepot, Sylvain, additional, Park, Sophie, additional, Couret, David, additional, Roux-Sauvat, Marielle, additional, Terriou, Louis, additional, Hachulla, Eric, additional, Bally, Cécile, additional, Galland, Joris, additional, Allain, Jean-Sébastien, additional, Parcelier, Anne, additional, Peterlin, Pierre, additional, Cohen-Bittan, Judith, additional, Regent, Alexis, additional, Ackermann, Felix, additional, Le Guen, Julien, additional, Algrin, Caroline, additional, Charles, Pierre, additional, Daguindau, Etienne, additional, Puechal, Xavier, additional, Dunogue, Bertrand, additional, Blanchard-Delaunay, Claire, additional, Beyne-Rauzy, Odile, additional, Grobost, Vincent, additional, Schmidt, Jean, additional, Le Gallou, Thomas, additional, Dubos-Lascu, Georgeta, additional, Sonet, Anne, additional, Denis, Guillaume, additional, Roy-Peaud, Frédérique, additional, Fenaux, Pierre, additional, Adès, Lionel, additional, Fain, Olivier, additional, and Mekinian, Arsène, additional

Published
2021
Full Text
View/download PDF

19. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Author

Letestu, Rémi, Dahmani, Abdelmalek, Boubaya, Marouane, Baseggio, Lucile, Campos, Lydia, Chatelain, Bernard, Debliquis, Agathe, Drénou, Bernard, Jacob, Marie-Christine, Legac, Eric, Le Garff-Tavernier, Magali, Lhoumeau, Anne-Catherine, Quiney, Claire, Robillard, Nelly, Ticchioni, Michel, Aanei, Carmen, Katsahian, Sandrine, Delepine, Roselyne, Vaudaux, Sandrine, Rouillé, Valérie, Béné, Marie-Christine, Dartigeas, Caroline, Van Den Neste, Eric, Leprêtre, Stéphane, Feugier, Pierre, Cartron, Guillaume, Leblond, Véronique, Lévy, Vincent, Cymbalista, Florence, Cailleres, Sylvie, Damaj, Gandhi, Royer, Bruno, Gardembas, Martine, Dib, Mamoun, Truchan-Graczyk, Matgorzata, Hunault, Mathilde, Foussard, Charles, Corront, Bernadette, Parry, Anne, Orsini-Piocelle, Frédérique, Trouillier, Sébastien, Slama, Bohiane, Lepeu, Gérard, Zerazhi, Hacene, Boulat, Olivier, Azzedine, Ahmed, Araujo, Carla, Banos, Anne, Bauduer, Frédéric, Dutel, Jean-Luc, Ghomari, Kamel, Deconinck, Eric, Brion, Annie, Vuillier, Jacqueline, Saad, Alain, El Yamani, Abderrazak, Rodon, Philippe, Soubeyran, Pierre, Etienne, Gabriel, Dilhuydy, Marie-Sarah, Bouabdallah, Krimo, Leguay, Thibaut, Chouffi, Bachra, Pollet, Bertrand, Maakaroun, Abdallah, Guillerm, Gaëlle, Berthou, Christian, Cheron, Nathalie, ANDRÉ, Marc, Vilque, Jean Pierre, Fruchart, Christophe, Voillat, Laurent, Pica, Gian Matteo, Corm, Sélim, Micléa, Jean-Michel, Souleau, Bertrand, Molucon-Chabrot, Cécile, De Renzis, Benoit, Tournilhac, Olivier, Bay, Jacques-Olivier, Chaleteix, Carine, Guieze, Romain, Fleury, Joel, Precupanu, Cristina, Bouledroua, Selwa, Haiat, Stéphanie, Petitdidier, Charlotte, Dupuis, Jehan, Belhadj, Karim, Casasnovas, Olivier, Bastie, Jean-Noel, Ferrant, Emmanuelle, Gholam, Dany, Molina, Lysiane, Garban, Frédéric, Tiab, Mourad, Maisonneuve, Hervé, Villemagne, Bruno, Jacomy, Dominique, Besson, Caroline, Tertian, Gérard, Laribi, Kamel, Morel, Pierre, Cazin, Bruno, Moreau, Stéphane, Reminieras, Liliane, Rapp, Marie-José, Moreau, Philippe, Sebban, Catherine, Michallet, Anne-Sophie, Salles, Gilles, Broussais, Florence, Aurran-Schleinitz, Thérèse, Coso, Diane, Abarah, Wajed, Kulekci, Claire, Dorvaux, Véronique, Carassou, Philippe, Guibaud, Isabelle, Christian, Bernard, Graux, Carlos, Rossi, Jean-François, Quittet, Philippe, Dubois, Alain, Eisenmann, Jean-Claude, Morineau, Nadine, Mahé, Béatrice, Karsenti, Jean-Michel, Jourdan, Eric, Legouffe, Eric, Alexis-Vigier, Magda, Boulet, Jean-Michel, Aoudjhane, Malek, Thiéblemont, Catherine, Andreoli, Anna Lisa, Dreyfus, François, Choquet, Sylvain, Maloum, Karim, Merle-Béral, Hélène, Vekhoff, Anne, Decaudin, Didier, Brault, Philippe, Delarue, Richard, Janvier, Maud, Soussain, Carole, Vallantin, Xavier, Sanhes, Laurence, Dreyfus, Brigitte, Tomowiak, Cécile, Benramdane, Riad, Gonzalez, Hugo, Blaise-Brenna, Anne, Kolb, Brigitte, Delmer, Alain, Dauriac, Charles, Houot, Roch, Escoffre-Barbe, Martine, Lamy, Thierry, De Guibert, Sophie, Bernard, Marc, Grosbois, Bernard, Brehar, Oana, Morice, Patrick, Guyotat, Denis, Jaubert, Jérome, Portois, Christelle, Fornecker, Luc-Matthieu, Herbrecht, Raoul, Bilger, Karin, Ame, Shanti, Ysebaert, Loic, Godmer, Pascal, Jardel, Henry, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Saint-Etienne, CHU UCL Namur, Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), CHU Grenoble, Centre Hospitalier Régional d'Orléans (CHRO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital Saint-Louis [AP-HP] (AP-HP), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Montpellier (UM), UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (MGD) Laboratoire de biologie clinique, UCL - (SLuc) Service d'hématologie, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)

Subjects
0301 basic medicine, Male, Cancer Research, Neoplasm, Residual, MESH: Immunotherapy, Chronic lymphocytic leukemia, Gastroenterology, MESH: Clinical Trials, Phase III as Topic, 0302 clinical medicine, Bone Marrow, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, MESH: Leukemia, Lymphocytic, Chronic, B-Cell, MESH: Aged, education.field_of_study, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, MESH: Follow-Up Studies, Prognosis, 3. Good health, Fludarabine, Survival Rate, Leukemia, MESH: Antineoplastic Combined Chemotherapy Protocols, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, MESH: Vidarabine, MESH: Bone Marrow, Female, MESH: Rituximab, Immunotherapy, Rituximab, MESH: Clinical Trials, Phase II as Topic, Vidarabine, medicine.drug, medicine.medical_specialty, Cyclophosphamide, MESH: Survival Rate, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, 03 medical and health sciences, Clinical Trials, Phase II as Topic, Chemoimmunotherapy, Internal medicine, medicine, Humans, education, Survival rate, MESH: Neoplasm, Residual, Aged, Retrospective Studies, MESH: Humans, business.industry, MESH: Cyclophosphamide, MESH: Retrospective Studies, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, MESH: Male, body regions, 030104 developmental biology, Clinical Trials, Phase III as Topic, Bone marrow, business, MESH: Female, Follow-Up Studies
Abstract

International audience; Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10-5) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD

Published
2020

20. Del17p without TP53 mutation confers poor prognosis in intensively treated newly diagnosed multiple myeloma patients

Author

Corre, Jill, Perrot, Aurore, Caillot, Denis, Belhadj, Karim, Hulin, Cyrille, Leleu, Xavier, Mohty, Mohamad, Facon, Thierry, Buisson, Laure, Do Souto, Laura, Lannes, Romain, Dufrechou, Stephanie, Prade, Nais, Orsini-Piocelle, Frédérique, Voillat, Laurent, Jaccard, Arnaud, Karlin, Lionel, Macro, Margaret, Brechignac, Sabine, Dib, Mamoun, Sanhes, Laurence, Fontan, Jean, Filliatre‐Clement, Lauriane, Marolleau, Jean Pierre, Minvielle, Stephane, Moreau, Philippe, Avet-Loiseau, Hervé, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Henri Mondor, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Institut François Magendie, Hôpital de la Milétrie, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Université Sorbonne Paris Cité (USPC), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service des Maladies du Sang [CHU Lille] (SMS), Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Centre Hospitalier Chalon-sur-Saône William Morey, CHU Limoges, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Saint Jean de Perpignan, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Amiens-Picardie, Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression (CRCINA-ÉQUIPE 11), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre hospitalier universitaire de Nantes (CHU Nantes), Bernardo, Elizabeth, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse], Service des Maladies du Sang [CHRU Lille], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)

Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer, [SDV.CAN]Life Sciences [q-bio]/Cancer
Abstract

International audience; Despite tremendous improvements in the outcome of patients with multiple myeloma (MM) in the past decade, high-risk patients have not benefited from the approval of novel drugs. The most important prognostic factor is the loss of parts of the short arm of chromosome 17, known as deletion 17p (del(17p)). A recent publication (on a small number of patients) suggested that these patients are at very high-risk only if del(17p) is associated with TP53 mutations, the so-called "double-hit" population. To validate this finding, we designed a much larger study on 121 patients presenting del(17p) in >55% of their plasma cells, and homogeneously treated by an intensive approach. For these 121 patients, we performed deep next generation sequencing targeted on TP53. The outcome was then compared to a large control population (2505 patients lacking del(17p)). Our results confirmed that the "double hit" situation is the worst (median survival = 36 months), but that del(17p) alone also confers a poor outcome compared with the control cohort (median survival = 52.8 months vs 152.2 months, respectively). In conclusion, our study clearly confirms the extremely poor outcome of patients displaying "double hit", but also that del(17p) alone is still a very high-risk feature, confirming its value as a prognostic indicator for poor outcome.

Published
2020

21. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

Author

Facon, Thierry, Mary, Jean Yves, Hulin, Cyrille, Benboubker, Lotfi, Attal, Michel, Pegourie, Brigitte, Renaud, Marc, Harousseau, Jean Luc, Guillerm, Gaëlle, Chaleteix, Carine, Dib, Mamoun, Voillat, Laurent, Maisonneuve, Hervé, Troncy, Jacques, Dorvaux, Véronique, Monconduit, Mathieu, Martin, Claude, Casassus, Philippe, Jaubert, Jérôme, Jardel, Henry, Doyen, Chantal, Kolb, Brigitte, Anglaret, Bruno, Grosbois, Bernard, Yakoub-Agha, Ibrahim, Mathiot, Claire, and Avet-Loiseau, Hervé

Published
2007
Full Text
View/download PDF

23. Single versus double autologous stem-cell transplantation for multiple myeloma

Author

Attal, Michel, Harousseau, Jean-Luc, Facon, Thierry, Guilhot, Francois, Doyen, Chantal, Fuzibet, Jean-Gabriel, Monconduit, Mathieu, Hulin, Cyrille, Caillot, Denis, Bouabdallah, Reda, Voillat, Laurent, Sotto, Jean-Jacques, Grosbois, Bernard, and Bataille, Regis

Subjects
Multiple myeloma -- Care and treatment, Hematopoietic stem cells -- Evaluation, Hematopoietic stem cells -- Transplantation
Abstract

Patients with multiple myeloma may benefit from receiving two autologous stem-cell transplants instead of one, according to a study of 399 patients. Patients who received two stem cell transplants had better outcomes and lived longer than those who received one stem cell transplant. An autologous transplant means the patient donated his or her own cells to be used in the transplant.

Published
2003

25. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol

Author

Moreau, Philippe, Hullin, Cyrille, Garban, Frédéric, Yakoub-Agha, Ibrahim, Benboubker, Lotfi, Attal, Michel, Marit, Gérald, Fuzibet, Jean-Gabriel, Doyen, Chantal, Voillat, Laurent, Berthou, Christian, Ketterer, Nicolas, Casassus, Philippe, Monconduit, Mathieu, Michallet, Mauricette, Najman, Albert, Sotto, Jean-Jacques, Bataille, Régis, and Harousseau, Jean-Luc

Published
2006
Full Text
View/download PDF

26. Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

Author

Attal, Michel, Lauwers-Cances, Valerie, Marit, Gerald, Caillot, Denis, Moreau, Philippe, Facon, Thierry, Stoppa, Anne Marie, Hulin, Cyrille, Benboubker, Lofti, Garderet, Laurent, Decaux, Olivier, Leyvraz, Serge, Vekemans, Marie-Christiane, Voillat, Laurent, Michallet, Mauricette, Pegourie, Brigitte, Dumontet, Charles, Roussel, Murielle, Leleu, Xavier, Mathiot, Claire, Payen, Catherine, Avet-Loiseau, Hervé, and Harousseau, Jean-Luc

Published
2012
Full Text
View/download PDF

27. Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome

Author

Yakoub-Agha, Ibrahim, Mary, Jean-Yves, Hulin, Cyrille, Doyen, Chantal, Marit, Gérald, Benboubker, Lotfi, Voillat, Laurent, Moreau, Philippe, Berthou, Christian, Stoppa, Anne-Marie, Maloisel, Frédéric, Rodon, Philippe, Dib, Mamoun, Pegourie, Brigitte, Casassus, Philippe, Slama, Borhane, Damaj, Ghandi, Zerbib, Robert, Harousseau, Jean-Luc, Mohty, Mohamad, and Facon, Thierry

Published
2012
Full Text
View/download PDF

28. Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study

Author

Tondeur, Sylvie, primary, Paul, Franciane, additional, Riou, Jérémie, additional, Mansier, Olivier, additional, Ranta, Dana, additional, Le Clech, Lenaïg, additional, Lippert, Eric, additional, Tavitian, Suzanne, additional, Chaoui, Driss, additional, Mercier, Mélanie, additional, De Renzis, Benoit, additional, Cottin, Laurane, additional, Cassinat, Bruno, additional, Chrétien, Jean-Marie, additional, Ianotto, Jean-Christophe, additional, Allangba, Olivier, additional, Marzac, Christophe, additional, Voillat, Laurent, additional, Boyer, Françoise, additional, Orvain, Corentin, additional, Hunault-Berger, Mathilde, additional, Girodon, François, additional, Kiladjian, Jean-Jacques, additional, Ugo, Valérie, additional, and Luque Paz, Damien, additional

Published
2020
Full Text
View/download PDF

29. Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia

Author

Rogier, Thomas, primary, Samson, Maxime, additional, Mourey, Guillaume, additional, Falvo, Nicolas, additional, Magy-Bertrand, Nadine, additional, Ouandji, Sethi, additional, Picque, Jean-Baptiste, additional, Greigert, Hélène, additional, Mausservey, Christelle, additional, Imbach, Arthur, additional, Ghesquière, Thibault, additional, Voillat, Laurent, additional, Caillot, Denis, additional, Deconinck, Eric, additional, Bonnotte, Bernard, additional, and Audia, Sylvain, additional

Published
2020
Full Text
View/download PDF

31. Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk

Author

Corre, Jill, primary, Montes, Lydia, additional, Martin, Elodie, additional, Perrot, Aurore, additional, Caillot, Denis, additional, Leleu, Xavier, additional, Belhadj, Karim, additional, Facon, Thierry, additional, Hulin, Cyrille, additional, Mohty, Mohamad, additional, Fontan, Jean, additional, Macro, Margaret, additional, Brechignac, Sabine, additional, Jaccard, Arnaud, additional, Stoppa, Anne-Marie, additional, Orsini-Piocelle, Frederique, additional, Adiko, Didier, additional, Voillat, Laurent, additional, Keddar, Faiza, additional, Barry, Marly, additional, Demarquette, Helene, additional, Certain, Marie-Noelle, additional, Plantier, Isabelle, additional, Roussel, Murielle, additional, Hébraud, Benjamin, additional, Filleron, Thomas, additional, Attal, Michel, additional, and Avet-Loiseau, Hervé, additional

Published
2020
Full Text
View/download PDF

32. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era

Author

Sesques, Pierre, primary, Bourcier, Jessie, additional, Golfier, Camille, additional, Lebras, Laure, additional, Nicolas‐Virelizier, Emmanuelle, additional, Hacini, Maya, additional, Perrin, Marie Claire, additional, Voillat, Laurent, additional, Bachy, Emmanuel, additional, Traverse‐Glehen, Alexandra, additional, Moreau, Anne, additional, Martin, Laurent, additional, Ramla, Selim, additional, Casasnovas, Olivier, additional, Le Gouill, Steven, additional, Salles, Gilles, additional, and Ghesquières, Hervé, additional

Published
2020
Full Text
View/download PDF

33. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V, Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M, Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves-Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J, Lipkin, Steven M, McKay, James D, Dumontet, Charles, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V, Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M, Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves-Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J, Lipkin, Steven M, McKay, James D, and Dumontet, Charles

Abstract

To the Editor, Multiple myeloma (MM) is the third most common hematological malignancy, after Non-Hodgkin Lymphoma and Leukemia. MM is generally preceded by Monoclonal Gammopathy of Undetermined Significance (MGUS) [1], and epidemiological studies have identified older age, male gender, family history, and MGUS as risk factors for developing MM [...]

Published
2019

34. Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Author

Leleu, Xavier, Fouquet, Guillemette, Richez, Valentine, Guidez, Stéphanie, Duhamel, Alain, Machuron, François, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, Malfuson, Jean Valère, Bourquard, Pascal, Lenain, Pascal, Roussel, Murielle, Jaccard, Arnaud, Pétillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gérard, Chrétien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Roos-Weil, Damien, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G, Attal, Michel, Moreau, Philippe, Avet-Loiseau, Herve, Hulin, Cyrille, Facon, Thierry, Leleu, Xavier, Fouquet, Guillemette, Richez, Valentine, Guidez, Stéphanie, Duhamel, Alain, Machuron, François, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, Malfuson, Jean Valère, Bourquard, Pascal, Lenain, Pascal, Roussel, Murielle, Jaccard, Arnaud, Pétillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gérard, Chrétien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Roos-Weil, Damien, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G, Attal, Michel, Moreau, Philippe, Avet-Loiseau, Herve, Hulin, Cyrille, and Facon, Thierry

Abstract

Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated that twice-weekly KMP (carfilzomib, melphalan, prednisone) might challenge the MPV (melphalan, prednisone, bortezomib) standard. We sought to study KMP weekly, allowing to increase carfilzomib's dose with maintained efficacy and improved safety profile., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2019

36. Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial

Author

Leleu, Xavier, primary, Fouquet, Guillemette, additional, Richez, Valentine, additional, Guidez, Stéphanie, additional, Duhamel, Alain, additional, Machuron, François, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Tiab, Mourad, additional, Araujo, Carla, additional, Meuleman, Nathalie, additional, Malfuson, Jean-Valère, additional, Bourquard, Pascal, additional, Lenain, Pascal, additional, Roussel, Murielle, additional, Jaccard, Arnaud, additional, Pétillon, Marie-Odile, additional, Belhadj-Merzoug, Karim, additional, Lepeu, Gérard, additional, Chrétien, Marie-Lorraine, additional, Fontan, Jean, additional, Rodon, Philippe, additional, Schmitt, Anna, additional, Offner, Fritz, additional, Voillat, Laurent, additional, Cereja, Sophie, additional, Kuhnowski, Frédérique, additional, Rigaudeau, Sophie, additional, Decaux, Olivier, additional, Humbrecht-Kraut, Catherine, additional, Frayfer, Jamile, additional, Fitoussi, Olivier, additional, Roos-Weil, Damien, additional, Eisenmann, Jean-Claude, additional, Dorvaux, Véronique, additional, Voog, Eric G., additional, Attal, Michel, additional, Moreau, Philippe, additional, Avet-Loiseau, Hervé, additional, Hulin, Cyrille, additional, and Facon, Thierry, additional

Published
2019
Full Text
View/download PDF

37. Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma

Author

Perrot, Aurore, primary, Lauwers-Cances, Valérie, additional, Tournay, Elodie, additional, Hulin, Cyrille, additional, Chretien, Marie-Lorraine, additional, Royer, Bruno, additional, Dib, Mamoun, additional, Decaux, Olivier, additional, Jaccard, Arnaud, additional, Belhadj, Karim, additional, Brechignac, Sabine, additional, Fontan, Jean, additional, Voillat, Laurent, additional, Demarquette, Hélène, additional, Collet, Philippe, additional, Rodon, Philippe, additional, Sohn, Claudine, additional, Lifermann, François, additional, Orsini-Piocelle, Frédérique, additional, Richez, Valentine, additional, Mohty, Mohamad, additional, Macro, Margaret, additional, Minvielle, Stéphane, additional, Moreau, Philippe, additional, Leleu, Xavier, additional, Facon, Thierry, additional, Attal, Michel, additional, Avet-Loiseau, Hervé, additional, and Corre, Jill, additional

Published
2019
Full Text
View/download PDF

38. Lenalidomide in Combination with CHOP in Patients with Angioimmunoblastic T-Cell Lymphoma (AITL): Final Analysis of Clinical and Molecular Data of a Phase 2 Lysa Study

Author

Lemonnier, Francois, primary, Safar, Violaine, additional, de Leval, Laurence, additional, Cottereau, Anne Ségolène, additional, Pelletier, Laura, additional, Robe, Cyrielle, additional, Bachy, Emmanuel, additional, Cartron, Guillaume, additional, Moles, Marie-Pierre, additional, Letourneau, Audrey, additional, Missiaglia, Edoardo, additional, Delmer, Alain Jacques, additional, Bouabdallah, Reda, additional, Voillat, Laurent, additional, Parrens, Marie, additional, Casasnovas, Olivier, additional, Cacheux, Victoria, additional, Gressin, Remy, additional, Tilly, Herve, additional, Delfau, Marie-Helene, additional, Meignan, Michel, additional, Gaulard, Philippe, additional, and Haioun, Corinne, additional

Published
2018
Full Text
View/download PDF

39. Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol

Author

Canioni, Danielle, primary, Brice, Pauline, additional, Bologna, Serge, additional, Voillat, Laurent, additional, Gabarre, Jean, additional, Casasnovas, Olivier, additional, Devidas, Alain, additional, Coiffier, Bertrand, additional, Aoudjhane, Malek, additional, Audhuy, Bruno, additional, Andre, Marc, additional, Fortpied, Catherine, additional, Carde, Patrice, additional, Mounier, Nicolas, additional, and Briere, Josette, additional

Published
2018
Full Text
View/download PDF

40. Light Chain Escape in Multiple Myeloma

Author

Dejoie, Thomas, primary, Fouquet, Guillemette, additional, Hulin, Cyrille, additional, Roussel, Murielle, additional, Hebraud, Benjamin, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Araujo, Carla, additional, Meuleman, Nathalie, additional, Tiab, Mourad, additional, Malfuson, Jean Valère, additional, Bourquard, Pascal, additional, Lenain, Pascal, additional, Jaccard, Arnaud, additional, Belhadj, Karim, additional, Lepeu, Gérard, additional, Chretien, Marie Lorraine, additional, Caillot, Denis, additional, Fontan, Jean, additional, Rodon, Philippe, additional, Schmitt, Anna, additional, Voillat, Laurent, additional, Cereja, Sophie, additional, Pegourie, Brigitte, additional, Kuhnowski, Frederique, additional, Rigaudeau, Sophie, additional, Decaux, Olivier, additional, Humbrecht-Kraut, Catherine, additional, Frayfer, Jamilé, additional, Garderet, Laurent, additional, Roos-Weil, Damien, additional, Eisenmann, Jean Claude, additional, Dorvaux, Veronique, additional, Voog, Eric G., additional, Mathiot, Claire, additional, Fermand, Jean-Paul, additional, Facon, Thierry, additional, Avet-Loiseau, Hervé, additional, Harousseau, Jean Luc, additional, Moreau, Philippe, additional, Attal, Michel, additional, and Leleu, Xavier, additional

Published
2018
Full Text
View/download PDF

42. Interleukin-2-induced increase of a monoclonal B-cell lymphocytosis: a novel in vivo interleukin-2 effect?

Author

Tiberghien, Pierre, Racadot, Evelyne, Deschaseaux, Marie L., Delain, Martine, Voillat, Laurent, Billot, Maryse, Flesch, Michel, Rozenbaum, Annie, Brandely, Maud, Cahn, Jean-Yves, and Herve, Patrick

Subjects
Lymphocytic leukemia -- Care and treatment, Non-Hodgkin's lymphomas -- Care and treatment, Interleukin-2 -- Health aspects, Immunotherapy -- Usage, B cells -- Physiological aspects, Health
Abstract

A 56-year-old man with refractory B-cell lymphocytic non-Hodgkin's lymphoma was treated in a Phase II study with interleukin-2 (IL-2) (Roussel-Uclaf, Romainville, France). The patient had involvement of multiple lymph nodes and medullary and peripheral blood (3.6 X [10.sup.9] monoclonal CD19-positive [CD19+] B-lymphocytes/l). After a 5-day cycle of IL-2 treatment, an eightford increase of the monoclonal CD19+ population was observed (27 X [10.sup.9] monoclonal CD19+ cells). The lymphocytosis decreased dramatically during the second cycle (days 15 to 19) of IL-2 treatment, resulting in 6 X [10.sup.9]/l peripheral lymphocytes, with 5.5 X [10.sup.9] B-lymphocytes. As soon as day 20, peripheral B-cells again increased considerably, with 32 X [10.sup.9] CD19+ cells/l at day 27. The CD19+ population remained monoclonal as assessed by kappa/lambda cell-surface phenotyping and kappa gene rearrangement evaluation. Kinetics of the monoclonal B-lymphocyte response to IL-2 paralleled the natural killer/lymphokine-activated killer and T-cell response, with a 4-day latency period, suggesting an indirect enhancing effect of IL-2. Before and during IL-2 treatment, peripheral B-lymphocytes never expressed detectable levels of the p55 IL-2 receptor. However, the p75 IL-2 receptor was expressed significantly in the IL-2-responsive monoclonal B-cell population. Tumor necrosis factor alpha, a known (in vitro) B-cell tumor growth factor, reached high serum levels during IL-2 treatment. Response evaluation at day 45 showed stability of the lymph node involvement and the marrow lymphocyte infiltrate. At day 45, peripheral B-cell lymphocytosis was 7.5 X [10.sup.9]/l. To the knowledge of the authors, this is the first report of an in vivo IL-2-induced reversible increase of peripheral monoclonal B-cell lymphocytosis. Cancer 1992; 69:2583-2588.

Published
1992

43. del(17p) without TP53mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma

Author

Corre, Jill, Perrot, Aurore, Caillot, Denis, Belhadj, Karim, Hulin, Cyrille, Leleu, Xavier, Mohty, Mohamad, Facon, Thierry, Buisson, Laure, Do Souto, Laura, Lannes, Romain, Dufrechou, Stephanie, Prade, Naïs, Orsini-Piocelle, Frederique, Voillat, Laurent, Jaccard, Arnaud, Karlin, Lionel, Macro, Margaret, Brechignac, Sabine, Dib, Mamoun, Sanhes, Laurence, Fontan, Jean, Clement-Filliatre, Lauriane, Marolleau, Jean-Pierre, Minvielle, Stephane, Moreau, Philippe, and Avet-Loiseau, Hervé

Abstract

Despite tremendous improvements in the outcome of patients with multiple myeloma in the past decade, high-risk patients have not benefited from the approval of novel drugs. The most important prognostic factor is the loss of parts of the short arm of chromosome 17, known as deletion 17p (del(17p)). A recent publication (on a small number of patients) suggested that these patients are at very high-risk only if del(17p) is associated with TP53mutations, the so-called “double-hit” population. To validate this finding, we designed a much larger study on 121 patients presenting del(17p) in > 55% of their plasma cells, and homogeneously treated by an intensive approach. For these 121 patients, we performed deep next generation sequencing targeted on TP53. The outcome was then compared with a large control population (2505 patients lacking del(17p)). Our results confirmed that the “double hit” situation is the worst (median survival = 36 months), but that del(17p) alone also confers a poor outcome compared with the control cohort (median survival = 52.8 months vs 152.2 months, respectively). In conclusion, our study clearly confirms the extremely poor outcome of patients displaying “double hit,“ but also that del(17p) alone is still a very high-risk feature, confirming its value as a prognostic indicator for poor outcome.

Published
2021
Full Text
View/download PDF

44. Long-term follow-up of JAK2exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study

Author

Tondeur, Sylvie, Paul, Franciane, Riou, Jérémie, Mansier, Olivier, Ranta, Dana, Le Clech, Lenaïg, Lippert, Eric, Tavitian, Suzanne, Chaoui, Driss, Mercier, Mélanie, De Renzis, Benoit, Cottin, Laurane, Cassinat, Bruno, Chrétien, Jean-Marie, Ianotto, Jean-Christophe, Allangba, Olivier, Marzac, Christophe, Voillat, Laurent, Boyer, Françoise, Orvain, Corentin, Hunault-Berger, Mathilde, Girodon, François, Kiladjian, Jean-Jacques, Ugo, Valérie, and Luque Paz, Damien

Published
2021
Full Text
View/download PDF

45. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Weisel, Katja, Doyen, Chantal, Dimopoulos, Meletios, Yee, Adrian, Lahuerta, Juan José, Martin, Amber, Travers, Karin, Druyts, Eric, Toor, Kabirraaj, Abildgaard, Niels, Lu, Jin, Van Droogenbroeck, Jan, Geraldes, Catarina, Petrini, Mario, Voillat, Laurent, Voog, Eric, Facon, Thierry, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Weisel, Katja, Doyen, Chantal, Dimopoulos, Meletios, Yee, Adrian, Lahuerta, Juan José, Martin, Amber, Travers, Karin, Druyts, Eric, Toor, Kabirraaj, Abildgaard, Niels, Lu, Jin, Van Droogenbroeck, Jan, Geraldes, Catarina, Petrini, Mario, Voillat, Laurent, Voog, Eric, and Facon, Thierry

Abstract

In newly diagnosed multiple myeloma (MM), patients ineligible for front-line autologous stem cell transplantation (ASCT), melphalan and prednisone (MP) with thalidomide (MPT) or bortezomib (VMP) are standard first-line therapeutic options. Despite new treatment regimens incorporating bortezomib or lenalidomide, MM remains incurable. The FIRST study demonstrated significant improvement in progression-free survival (PFS) and overall survival (OS) for the combination of lenalidomide and low-dose dexamethasone (Rd) until progression vs. MPT in transplant-ineligible ndMM patients. However, to date no head-to-head randomized controlled trials (RCTs) have compared Rd or MPT versus VMP. We conducted a network meta-analysis using RCTs identified through a systematic literature review to evaluate the relative efficacy of Rd versus other regimens on survival endpoints in previously untreated MM patients ineligible for ASCT. In this analysis, Rd was associated with a significant PFS and survival advantage versus other first-line treatments (VMP, MPT, MP), challenging the role of alkylators in this setting.

Published
2017

46. Serum free light chains should be the target of response evaluation in light chain multiple myeloma rather than urines

Author

Dejoie, Thomas, Corre, Jill, Caillon, Helene, Hulin, Cyrille, Perrot, Aurore, Caillot, Denis, Boyle, Eileen, Chretien, Marie-Lorraine, Fontan, Jean, Belhadj, Karim, Brechignac, Sabine, Decaux, Olivier, Voillat, Laurent, Rodon, Philippe, Fitoussi, Olivier, Araujo, Carla, Benboubker, Lotfi, Fontan, Charlotte, Tiab, Mourad, Godmer, Pascal, Luycx, Odile, Allangba, Olivier, Pignon, Jean-Michel, Fuzibet, Jean-Gabriel, Legros, Laurence, Stoppa, Anne-Marie, Dib, Mamoun, Pegourie, Brigitte, Orsini-Piocelle, Frederique, Karlin, Lionel, Arnulf, Bertrand, Roussel, Murielle, Garderet, Laurent, Mohty, Mohamad, Meuleman, Nathalie, Doyen, Chantal, Lenain, Pascal, Macro, Margaret, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Herve, UCL - (MGD) Service d'hématologie, and UCL - SSS/IREC/MONT - Pôle Mont Godinne

Abstract

Guidelines for monitoring multiple myeloma patients expressing light chains only (light chain multiple myeloma; LCMM) rely on measurements of the monoclonal protein in urine. Alternatively serum free light chain (sFLC) measurements have better sensitivity over urine methods, however, demonstration that improved sensitivity provides any clinical benefit is lacking. Here we compared the performance of serum and urine measurements in 113 (72κ, 41λ) newly diagnosed LCMM patients enrolled onto the IFM-2009 trial. All diagnostic samples (100%) had an abnormal κ/λ sFLC ratio, and involved (monoclonal) FLC (iFLC) expressed at levels deemed measurable for monitoring (≥100mg/L). By contrast, only 64% patients had measurable levels of the monoclonal protein (≥200mg/24h) in urine protein electrophoresis (UPEP). After 1 and 3 treatment cycles, iFLC remained elevated in 71% and 46% patients, respectively, whilst UPEP reported a positive result in 37% and 18%; all the patients with a positive UPEP at cycle 3 also had elevated iFLC levels. Importantly, elevated iFLC or an abnormal κ/λ sFLC ratio after 3 treatment cycles associated with poorer PFS (p=0.006 and p

Published
2016

47. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) / 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL

Author

Leleu, Xavier, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, De Revel, Thierry, Bourquard, Pascal, Lenain, Pascal, Roussel, Murielle, Jaccard, Arnaud, Petillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gerard, Chretien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frederique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Weil, Damien Roos, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G., Hulin, Cyrille, Attal, Michel, Moreau, Philippe, Facon, Thierry, Service d'Hématologie, Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Général de La Roche sur Yon, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), CHU Pontchaillou [Rennes], Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Henri Duffaut (Avignon), Lipides - Nutrition - Cancer (U866) (LNC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bourgogne (UB)-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Chalon-sur-Saône William Morey, Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier de Meaux, Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Laboratoire d'Hématologie [Rangueil], Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Service d'Hématologie Clinique, Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Claude Huriez [Lille], CHU Lille, Jonchère, Laurent, Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

WOS:000368020103223; International audience; Conference: 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL - DEC 05-08, 2015

Published
2015

48. Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods

Author

Corre, Jill, Perrot, Aurore, Hulin, Cyrille, Caillot, Denis, Stoppa, Anne-Marie, Facon, Thierry, Leleu, Xavier, Dib, Mamoun, Karlin, Lionel, Moreau, Philippe, Mohty, Mohamad, Mariette, Clara, Fontan, Jean, Marolleau, Jean-Pierre, Demarquette, Hélène, Slama, Borane, Voillat, Laurent, Macro, Margaret, Orsini-Piocelle, Frédérique, Brechignac, Sabine, Rey, Philippe, Collet, Philippe, Tiab, Mourad, Belhadj, Karim, Lifermann, François, Clement-Filliatre, Lauriane, Sohn, Claudine, Richez, Valentine, and Avet-loiseau, Hervé

Published
2021
Full Text
View/download PDF

49. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

Author

Leleu, Xavier, primary, Fouquet, Guillemette, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Tiab, Mourad, additional, Araujo, Carla, additional, Bourquard, Pascal, additional, Lenain, Pascal, additional, Roussel, Muriel, additional, Jaccard, Arnaud, additional, Petillon, Marie-Odile, additional, Belhadj-Merzoug, Karim, additional, Lepeu, Gérard, additional, Chretien, Marie-Lorraine, additional, Fontan, Jean, additional, Rodon, Philippe, additional, Schmitt, Anna, additional, Voillat, Laurent, additional, Cereja, Sophie, additional, Kuhnowski, Frédérique, additional, Rigaudeau, Sophie, additional, Decaux, Olivier, additional, Frayfer, Jamile, additional, Fitoussi, Olivier, additional, Roos Weil, Damien, additional, Eisenmann, Jean-Claude, additional, Dorvaux, Véronique, additional, Voog, Eric, additional, Hulin, Cyrille, additional, and Attal, Michel, additional

Published
2017
Full Text
View/download PDF

50. Clinical Efficacy of the Rivbd Combination for Refractory/Relapsed (R/R) Mantle Cell Lymphoma (MCL) Patients: A Retrospective Study of the French Lysa Group

Author

Régny, Caroline, primary, Malak, Sandra, additional, Manson, Guillaume, additional, Sarkozy, Clementine, additional, Clavert, Aline, additional, Herbaux, Charles, additional, Chauchet, Adrien, additional, Jourdan, Eric, additional, Sanhes, Laurence, additional, Godmer, Pascal, additional, Pascal, Laurent, additional, Le Du, Katell, additional, Sutton, Laurent, additional, Voillat, Laurent, additional, Dupuis, Jehan, additional, Anglaret, Bruno, additional, and Gressin, Remy, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results